Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply.
Saved in:
| Title: | Editorial: Does Metabolic Dysfunction-Associated Steatotic Liver Disease With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease? Authors' Reply. |
|---|---|
| Authors: | Zhou XD; MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China., Yilmaz Y; Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.; Liver Research Unit, Institute of Gastroenterology, Marmara University, İstanbul, Turkey., Zheng MH; MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2026 Jan; Vol. 63 (1), pp. 155-156. Date of Electronic Publication: 2025 Aug 13. |
| Publication Type: | Editorial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
